Protocolo diagnóstico de la miocardiopatía secundaria a tratamientos oncológicos

  1. López-Fernández, T.
  2. Canales Albendea, M.
  3. Buño Soto, A.
  4. Feliu, J.
  5. Rodríguez, I.
  6. Moreno Yangüela, M.
  7. López Sendón, J.L.
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2017

Issue Title: Enfermedades cardiológicas (IX) Miocardiopatías

Series: 12

Issue: 43

Pages: 2593-2595

Type: Article

DOI: 10.1016/J.MED.2017.10.016 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Abstract The term cardio-oncology refers to monitoring and risk stratification throughout the stages of cancer, to minimize or eliminate cardiovascular complications, as well as early termination of potentially curative treatments. These objectives can only be achieved with a multidisciplinary approach. The development of local monitoring protocols that adapt the general recommendations to the means available in each centre is a critical step in the management of cardiotoxicity. The protocol for the prevention and early diagnosis of cardiomyopathy secondary to cancer treatments of the Cardio-Oncology Unit of University Hospital La Paz is summarized below.

Bibliographic References

  • Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102-11.
  • Zamorano JL, Lancellotti P, Rodríguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801.
  • Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L. Expert consensus for multimodality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the EACVI and the ASE. J Am Soc Echocardiogr. 2013;26:1013-32.
  • López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García Sanz R, Mazón Ramos P. CardioOncoHematología en la práctica clínica. Documento de consenso y recomendaciones. Rev Esp Cardiol. 2017;70(6):474-86.
  • Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. JACC. 2015;65:2739-46.
  • Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9): 911-39.
  • Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol. 2016;32:831-41.
  • Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the ASE and the EACVI. J Am Soc Echocardiogr. 2015;28:1-39.
  • Kou S, Caballero L, Dulgheru R, Voilliot D, De Sousa C, Kacharava G. Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. Eur Heart J Cardiovasc Imaging. 2014;156:680-90.
  • Romond E, Jeong JH, Rastogi P, Swain SM, Geyer CE, Ewer MS. Seven year followup assessment of cardiac function in NSA-BP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol. 2012;30:3792-9.
  • López-Fernández T, Thavendiranathan P. Emerging cardiac imaging modalities for the early detection of cardiotoxicity due to anticancer therapies. Rev Esp Cardiol. 2017;70(6):487-95
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129-200.
  • Hamo C, Bloom M, Cardinale D, Ky B, Nohria A, Baer L. Cancer therapy : related cardiac dysfunction and heart failure part 2: prevention, treatment, guidelines, and future directions. Circ Heart Fail. 2016;9:e002843.
  • Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213-20.
  • Armenian SH, Lacchetti C, Lenihan D. prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017;13(4):270-5.
Data source: Dialnet